Caring Brands, Inc. (CABR) 股票分析

公司概述

Caring Brands, Inc. operates as a wellness consumer products company that focuses on providing over-the-counter and cosmetic consumer products for specific dermatological and hair care needs. The enterprise functions within the Healthcare sector, specifically under the industry classification of Drug Manufacturers - Specialty & Generic, which implies a concentration on developing and distributing specialized pharmaceutical or cosmetic formulations rather than broad-spectrum medications. The company's current scale is defined by a market capitalization of $17.24M and an annual revenue of $4,215, while the employee count is listed as N/A, indicating a lack of publicly disclosed headcount data or a micro-cap structure. These financial dimensions suggest that Caring Brands, Inc. maintains a very small market footprint relative to its peers, operating with minimal revenue generation compared to the multi-billion dollar scales typical of established healthcare giants, which constrains its ability to leverage economies of scale in manufacturing and distribution.

财务健康

The company reported a revenue of $4,215 over the trailing twelve months, yet this top-line figure masks a significant operational deficit as the net income stands at -$6,278,191 and the EBITDA is -$3,085,025. The substantial gap between the nominal revenue and the massive negative net income reveals a cost structure where expenses, likely including significant R&D, sales, and general administrative costs, far exceed the gross proceeds from product sales. Free cash flow is recorded at -$670,666, indicating that the company is burning cash reserves to fund its operations and strategic initiatives rather than generating surplus liquidity for debt reduction or share repurchases. The gross margin stands at 55.6%, which suggests that the cost of goods sold is less than half of the revenue, providing a healthy markup on individual units before overheads are considered. However, the operating margin is reported as -326658.1% and the profit margin is 0.0%, figures that mathematically reflect the severe losses relative to the small revenue base and indicate that operating expenses are disproportionately high compared to earnings. The balance sheet shows cash holdings of $2.19M against total debt of $58,650, resulting in a debt-to-equity ratio of 2.80, which technically indicates a leveraged position despite the low absolute debt amount due to the small equity base. The current ratio of 13.16 demonstrates an extremely strong short-term liquidity position, suggesting the company possesses ample current assets to cover its short-term liabilities without immediate distress. Furthermore, the return on equity is -217.1% and the return on assets is -68.2%, metrics that reveal management is currently destroying shareholder value and failing to generate returns on the capital deployed to run the business.

估值评估

The trailing P/E ratio is N/A and the forward P/E is also N/A, which implies that earnings are currently negative and therefore traditional price-to-earnings metrics cannot be calculated to assess expected earnings trajectory or future profitability expectations. The price-to-book ratio is 8.24, indicating that the market values the company's equity at more than eight times its book value, which is a significant premium for a firm generating substantial losses and suggests high market expectations for future turnaround or asset value realization. The price-to-sales ratio is an extreme 4090.68, and the EV/EBITDA is -3.99, suggesting that alternative valuation metrics are distorted by the lack of profitability and that the stock price is decoupled from current sales performance or earnings generation. The 52-week high is $1.65 and the 52-week low is $0.71, placing the current trading environment within a highly volatile range defined by these historical extremes. Without a specific beta value provided in the data, the volatility relative to the broader market cannot be quantified, but the wide spread between the high and low implies significant price swings typical of small-cap biotech or specialty drug manufacturers.

Growth & Income

The revenue growth year-over-year is -9.7%, while earnings growth is N/A due to the lack of positive earnings in the prior period for comparison, indicating that the company is currently shrinking in sales rather than expanding its market share. Since the company does not pay dividends as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders, implying that any retained earnings—which are currently negative—could theoretically be reinvested into growth initiatives if profitability were restored. The absence of a sustainable dividend payout aligns with the financial reality that the company cannot support regular shareholder distributions while operating at a significant net loss and burning cash. Overall, the growth and income profile is characterized by declining revenue, negative earnings, no dividend income, and a high-risk capital structure that prioritizes survival and potential product development over immediate shareholder returns.